

APPENDIX 1 Voting frequency for the candidate studies (N=47 responses)

Trial	n	%
Empagliflozin in Heart Failure with a Preserved Ejection Fraction (EMPEROR-Preserved)	9	19.1
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (DELIVER)	9	19.1
Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME)	7	14.9
Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension (STEP)	5	10.6
Side Effect Patterns in a Crossover Trial of Statin, Placebo and No Treatment (SAMSON)	4	8.5
Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation (INVICTUS)	3	6.4
Effect of Salt Substitution on Cardiovascular Events and Death (SSaSS)	2	4.3
Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET)	2	4.3
Treatment for mild chronic hypertension during pregnancy (CHAP)	2	4.3
Polypill strategy in secondary cardiovascular prevention (SECURE)	2	4.3
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes (FIGARO-DKD)	1	2.1
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military	1	2.1
Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease (CLICK)	0	0.0
Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF)	0	0.0
Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease	0	0.0

Barry AR, et al. Review of the top 5 cardiology studies of 2021-22. Can Pharm J (Ott) 2023;156. DOI: 10.1177/17151635231176267.